title: Clinical significance of TMPRSS4 in prostate cancer.
abstract: Transmembrane protease serine 4 (TMPRSS4) is a type-II transmembrane serine protease that plays an important role in the migration of cancer cells. This study aimed to investigate both the expression of TMPRSS4 and its clinical significance in prostate cancer. The expression of TMPRSS4 was evaluated in 73 pairs of prostate cancer and adjacent non-cancerous tissues by immunohistochemistry. The level of TMPRSS4 in prostate cancer tissues was significantly higher than that in adjacent non-cancerous tissues. High TMPRSS4 expression was significantly associated with advanced TNM stage and LNM. No association between TMPRSS4 expression and progression-free survival was observed in all patients. Stratified analyses according to clinical features revealed that patients with low TMPRSS4 expression had poor prognosis compared with those with high TMPRSS4 expression in subjects not receiving neoadjuvant chemotherapy. In conclusion, TMPRSS4 showed abnormal expression in prostate cancer tissues. TMPRSS4 may be a potential prognostic biomarker for prostate cancer patients who did not undergo neoadjuvant chemotherapy.
authors.affiliation: Department of Urology, Shanghai Cancer Center, Fudan University Shanghai 200032, China ; Department of Oncology, Shanghai Medical College, Fudan University Shanghai 200032, China.
authors.forename: Guohai
authors.initials: G
authors.lastname: Shi
authors.affiliation: Department of Oncology, Shanghai Medical College, Fudan University Shanghai 200032, China ; Department of Pathology, Shanghai Cancer Center, Fudan University Shanghai 200032, China.
authors.forename: Xiaoqun
authors.initials: X
authors.lastname: Yang
authors.affiliation: Department of Urology, Shanghai Cancer Center, Fudan University Shanghai 200032, China ; Department of Oncology, Shanghai Medical College, Fudan University Shanghai 200032, China.
authors.forename: Bo
authors.initials: B
authors.lastname: Dai
authors.affiliation: Department of Urology, Shanghai Cancer Center, Fudan University Shanghai 200032, China ; Department of Oncology, Shanghai Medical College, Fudan University Shanghai 200032, China.
authors.forename: Hailiang
authors.initials: H
authors.lastname: Zhang
authors.affiliation: Department of Urology, Shanghai Cancer Center, Fudan University Shanghai 200032, China ; Department of Oncology, Shanghai Medical College, Fudan University Shanghai 200032, China.
authors.forename: Yijun
authors.initials: Y
authors.lastname: Shen
authors.affiliation: Department of Urology, Shanghai Cancer Center, Fudan University Shanghai 200032, China ; Department of Oncology, Shanghai Medical College, Fudan University Shanghai 200032, China.
authors.forename: Yao
authors.initials: Y
authors.lastname: Zhu
authors.affiliation: Department of Urology, Shanghai Cancer Center, Fudan University Shanghai 200032, China ; Department of Oncology, Shanghai Medical College, Fudan University Shanghai 200032, China.
authors.forename: Yiping
authors.initials: Y
authors.lastname: Zhu
authors.affiliation: Department of Urology, Shanghai Cancer Center, Fudan University Shanghai 200032, China ; Department of Oncology, Shanghai Medical College, Fudan University Shanghai 200032, China.
authors.forename: Wenjun
authors.initials: W
authors.lastname: Xiao
authors.affiliation: Department of Urology, Shanghai Cancer Center, Fudan University Shanghai 200032, China ; Department of Oncology, Shanghai Medical College, Fudan University Shanghai 200032, China.
authors.forename: Chunguang
authors.initials: C
authors.lastname: Ma
authors.affiliation: Department of Urology, Shanghai Cancer Center, Fudan University Shanghai 200032, China ; Department of Oncology, Shanghai Medical College, Fudan University Shanghai 200032, China.
authors.forename: Linguo
authors.initials: L
authors.lastname: Wen
authors.affiliation: Department of Urology, Shanghai Cancer Center, Fudan University Shanghai 200032, China ; Department of Oncology, Shanghai Medical College, Fudan University Shanghai 200032, China.
authors.forename: Xiaojian
authors.initials: X
authors.lastname: Qin
authors.affiliation: Department of Urology, Shanghai Cancer Center, Fudan University Shanghai 200032, China ; Department of Oncology, Shanghai Medical College, Fudan University Shanghai 200032, China.
authors.forename: Dalong
authors.initials: D
authors.lastname: Cao
authors.affiliation: Department of Urology, Shanghai Cancer Center, Fudan University Shanghai 200032, China ; Department of Oncology, Shanghai Medical College, Fudan University Shanghai 200032, China.
authors.forename: Dingwei
authors.initials: D
authors.lastname: Ye
mesh_terms: D000230:Adenocarcinoma / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000378:metabolism; D018572:Disease-Free Survival; D006801:Humans; D008207:Lymphatic Metastasis / Q000473:pathology*; D008297:Male; D008565:Membrane Proteins / Q000378:metabolism*; D008875:Middle Aged; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D012697:Serine Endopeptidases / Q000378:metabolism*; D015996:Survival Rate
chemical_list: D014408:Biomarkers, Tumor; D008565:Membrane Proteins; D012697:Serine Endopeptidases; C528837:TMPRSS4 protein, human
keywords: Transmembrane protease; biomarker; neoadjuvant chemotherapy; prognosis; prostatic cancer; serine 4